Addressing Antiretroviral Drug Resistance with Host-Targeting Drugs—First Steps towards Developing a Host-Targeting HIV-1 Assembly Inhibitor

Abstract

The concerning increase in HIV-1 resistance argues for prioritizing the development of host-targeting antiviral drugs because such drugs can offer high genetic barriers to the selection of drug-resistant viral variants. Targeting host proteins could also yield drugs that act on viral life cycle events that have proven elusive to inhibition, such as intracellular events of HIV-1 immature capsid assembly. Here, we review small molecule inhibitors identified primarily through HIV-1 self-assembly screens and describe how all act either narrowly post-entry or broadly on early and late events of the HIV-1 life cycle. We propose that a different screening approach could identify compounds that specifically inhibit HIV-1 Gag assembly, as was observed when a potent rabies virus inhibitor was identified using a host-catalyzed rabies assembly screen. As an example of this possibility, we discuss an antiretroviral small molecule recently identified using a screen that recapitulates the host-catalyzed HIV-1 capsid assembly pathway. This chemotype potently blocks HIV-1 replication in T cells by specifically inhibiting immature HIV-1 capsid assembly but fails to select for resistant viral variants over 37 passages, suggesting a host protein target. Development of such small molecules could yield novel host-targeting antiretroviral drugs and provide insight into chronic diseases resulting from dysregulation of host machinery targeted by these drugs.

Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy

“…Hence, effective additional antiviral treatment options are needed, and combinations of metabolic drugs such as 2DG and BOT may play a role in COVID-19 therapies in the future. In this context, strategies that target the host cell instead of viral targets have been postulated to be potentially associated with reduced resistance formation [ 41 , 42 ].…”

Tetraspanins: Host Factors in Viral Infections

“…Currently, the assembly of HIV-1 virions remains largely controversial, with research distributed between two different models: the spontaneous/self-assembly model or the host-catalyzed model [ 76 , 77 ]. Agreement between the two models lies with HIV-1 polyprotein Gag and Gag-RNA interactions driving virion assembly [ 76 ].…”

The Importance of Cellular Immune Response to HIV: Implications for Antibody Production and Vaccine Design

“…Extremely powerful therapies exist nowadays to control HIV-1 infection, based on the antiretroviral drugs that have been developed and improved in the last 20 years to reduce the virus infectivity, stop the virus replication, and therefore limit the virus aggressiveness. Nevertheless, antiretroviral drugs can cause virus resistance in many patients chronically infected, especially in countries where the drugs are still too expensive for the majority of the patients and the correct compliance and adherence are challenging (Lingappa, Lingappa et al , 2021 ; Mbhele et al , 2021 ).…”